Pfizer、BMS和Perrigo在2025年10月提请分析家注意高股息、强劲的现金流动以及尽管Perrigo收入微乎其微,但前景却参差不齐。 Pfizer, BMS, and Perrigo drew analyst attention in Oct 2025 for high dividends, strong cash flows, and mixed outlooks despite Perrigo’s weak earnings.

2025年10月,华尔街顶尖分析家Pfizer、Bristol-Myers Squibb和Perrigo对Pfizer、Bristol-Myers Squibb和Perrigo的股息收益超过3%表示关注,而Pfizer的股息收益高达7.01%。 In October 2025, Pfizer, Bristol-Myers Squibb, and Perrigo were spotlighted by top Wall Street analysts for dividend yields above 3%, with Pfizer leading at 7.01%. 分析家维持了好坏参半的评级,但提高了或调整了价格目标,他们引用了强劲的现金流动和最近的发展动态,如辉瑞的积极的临床试验结果和布里斯托尔-迈尔斯·斯基布的ALS研究扩张。 Analysts maintained mixed ratings but raised or adjusted price targets, citing strong cash flows and recent developments like Pfizer’s positive clinical trial results and Bristol-Myers Squibb’s ALS research expansion. Perrigo报告收入微薄,尽管继续获得积极评级,但仍促使目标削减。 Perrigo reported weak earnings, prompting target cuts despite continued positive ratings.